Viewing Study NCT01755923

Bugs

Ignite Creation Date: 2025-12-18 @ 8:20 AM

Ignite Modification Date: 2025-12-23 @ 10:50 PM

Study NCT ID: NCT01755923

Status:

Last Update Posted:

First Post:

Is Possible Gene Therapy: False

Has Adverse Events: False

Brief Title: Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC

Sponsor:

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Contacts Locations Module Design Module Eligibility Module Outcomes Module References Module